The French pharmaceutical company "Sanofi" has announced that the "Plaquenil" drug produced by the company for malaria treatment has shown promising results in treating Covid-19 patients, according to Libyan Pharmacists Association Facebook page.

"The anti-malarial drug Plaquenil is made up of hydroxychloroquine molecules used to treat malaria caused by mosquito bites, in addition to autoimmune diseases like lupus or rheumatoid arthritis," Libyan Pharmacists Association explained.

In this context, an AFP official revealed that studies on patients with coronavirus using Plaquenil had come out promising, adding that the company is ready to offer millions of doses of Plaquenil, sufficient to treat 300,000 COVID-19 patients as a first stage.

This Plaquenil drug is in good supply and affordable in many Arab countries, as it is has been used for decades for treating malaria cases, according to the Libyan Pharmacists Association.